Trial Profile

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMT 151 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Lung cancer; Male breast cancer; Malignant-mesothelioma; Ovarian cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Multitude Therapeutics

Most Recent Events

29 Jan 2023 Status changed from not yet recruiting to recruiting.
04 Jan 2023 Planned initiation date changed from 20 Dec 2022 to 30 Jan 2023.
02 Dec 2022 Planned initiation date changed from 1 Oct 2022 to 20 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com